Keeping Track: New Drugs For IBS, LAM; New NDAs for HCV and Hyperkalemia
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Viberzi and Xifaxan share an indication and an approval date, but not much else.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Wave’s Duchenne muscular dystrophy drug and Lilly’s chronic pain R&D will test the agency’s CID meeting pilot program, while FDA issues draft guidance that highlights potential uses for complex innovative trial designs.